@entity2727 treatment in XXXX with borderline IQ and mental retardation: analysis of three aggregated studies.

@entity1 @entity71 @entity7541 @entity258 @entity2727
OBJECTIVE: To determine response of @entity258 @entity1 with @entity71 ( @entity71 ) symptoms to @entity2727 ( @entity7541 ). METHODS: An aggregated analysis was conducted in 90 @entity1 with @entity258 who received the same dose regimen of @entity7541 in three independent, placebo-controlled studies. Active drug and placebo were given from 2 to 4 weeks each. Outcome measures included teacher and parent ratings on standardized behavior scales (mean n = 84), performance on computer-controlled cognitive-motor tests (n = 62), and measures of cardiovascular response (n = 85). RESULTS: Both teachers and parents rated the @entity1 consistently as being improved on subscales assessing attention, overactivity, and conduct problems. Some 44% of the subjects showed at least a 30% reduction compared with placebo on teacher ratings. @entity7541 improved accuracy on several cognitive tests, response speed was increased on some, and seat activity declined for one of three tests; heart rate was mildly increased (3.9 beats/minute) with @entity7541 . Analyses of IQ and mental age as moderator variables suggested that lower functional level (especially lower IQ) may be associated with a less favorable response to @entity7541 . CONCLUSIONS: @entity1 with @entity258 and @entity71 clearly respond to @entity7541 , but their rate of beneficial response appears to be well under that of normal-IQ @entity1 and more varied. Different attentional mechanisms may moderate response to psychostimulants.
